Sirolimus: A potent new immunosuppressant for liver transplantation

Transplantation

Volumn 67, Issue 4, 1999, Pages 505-509

  Watson, Christopher J E ^a,b   Friend, Peter J ^a   Jamieson, Neville V ^a   Frick, Thomas W ^a   Alexander, Graeme ^c   Gimson, Alexander E ^c   Calne, Roy ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG POTENCY; DRUG TOLERANCE; DRUG WITHDRAWAL; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART ARREST; HEMIDIAPHRAGM; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; PARALYSIS; PRIORITY JOURNAL; SEPSIS; TUMOR RECURRENCE;

EID: 0033608450     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902270-00002     Document Type: Article

References (16)

1. Pai SY, Calvo V, Wood M, Bierer BE. Cross-linking CD28 leads to activation of 70-kDa S6 kinase. Eur J Immunol 1994; 24 (10): 2364.
2. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369 (6483): 756.
3. Sabatini DM, Erdjument Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78 (1): 35.
4. Stan R, McLaughlin MM, Cafferkey R, Johnson RK, Rosenberg M, Livi GP. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J Biol Chem 1994; 269 (51): 32027.
5. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270 (2): 815.
6. Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8 (6): 391.
7. Murgia M, Jordan S, Kahan B. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisolone-treated renal transplant patients. Kidney Int 1996; 49: 209.
8. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [letter]. Lancet 1989; 2 (8656): 227.
9. Collier DS, Calne R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990; 22 (4): 1674.
10. Collier DS, Calne RY, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23 (4): 2246.
11. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55 (4): 947.
12. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991; 51 (2): 486.
13. Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S. Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. Transplant Proc 1991; 23 (1 Part 2): 1090.
14. Sehgal S, Molnar-Kimber K, Ocain T, Weichman B. Rapamycin: a novel macrolide. Med Res Rev 1994; 14: 1.
15. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257 (5072): 973.
16. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27 (3): 2068.